FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
30/04/2026
Voltar para busca
Dado oficial do USPTO
FOSUN PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
01/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 35, 42
Data de depósito
05/07/2024
Data de registro
07/10/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/10/2025
Última transação
01/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
CN
Examinador
FRUM MILONE, MARCIE R
Unidade examinadora
M70
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording FOSUNPHARMA.
Titulares e representantes
Titulares
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Representantes
John Alumit ALUMIT IP
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 35Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Antiseptics; chemico-pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; anaesthetics; pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; vaccines; anti-inflammatory preparations; pharmaceuticals for the treatment of infectious diseases; pharmaceutical preparations to be inhaled for the prevention and treatment of respiratory diseases and disorders; pharmaceuticals for the treatment of cancer; balsamic preparations for medical purposes; drugs for medical purposes being pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; biological preparations for medical purposes being pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; medicines for human purposes being pharmaceutical preparations for the treatment of infectious-related diseases, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, metabolic diseases, anti-viral diseases, oncologic diseases; diagnostic reagents for medical purposes; pharmaceuticals for the treatment of viral diseases; diagnostic preparations for medical purposes
Classe 10
Medical apparatus and instruments for use in treating all treatable diseases, illnesses, and medical conditions for humans
Classe 35
Retail store or wholesale store services for medical supplies; retail store or wholesale store services for medicines; retail store or wholesale store services for pharmaceutical preparations; marketing services; sales promotion for others
Classe 42
Pharmaceutical drug development; pharmaceutical research; conducting clinical trials for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/04/2026
FIMP
FINAL DISPOSITION PROCESSED
12/04/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
09/04/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/03/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
23/03/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/01/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/10/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
07/10/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/10/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/08/2025
PUBO
PUBLISHED FOR OPPOSITION
19/08/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/08/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/07/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
15/07/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
15/07/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
15/07/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
15/07/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/07/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/07/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/07/2025
RFNT
REFUSAL PROCESSED BY IB
19/04/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/04/2025
RFRR
REFUSAL PROCESSED BY MPU
03/04/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/02/2025
CNRT
NON-FINAL ACTION WRITTEN
27/02/2025
DOCK
ASSIGNED TO EXAMINER
29/12/2024
MAFR
APPLICATION FILING RECEIPT MAILED
25/10/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/10/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/10/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace FOSUN PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.